Decreased nitric oxide synthase (NOS) activity induces left ventricular hypertrophy (LVH), but the transcriptional pathways mediating this effect are unknown. We hypothesized that specific NOS isoform deletion (NOS3 or NOS1) would activate different transcriptional programs in LVH. We analyzed cardiac expression profiles (Affymetrix MG U74A) from NOS -/-mice using robust multi-array average (RMA 
Introduction:
Left ventricular hypertrophy (LVH) may be defined as an increase in cardiac myocyte size accompanied by remodeling of the interstitial matrix and gross cardiac enlargement. LVH is a characteristic pathologic feature of common heart diseases such as congestive heart failure and hypertension, and is an independent predictor of cardiovascular death (15) . As a result, the pathogenesis of LVH has been a major focus of cardiovascular research. A number of insults have been shown to induce LVH, including mechanical overload, oxidative stress, neurohormonal activation, and inherited mutations in sarcomeric proteins (reviewed in 17, 26, 27, 30, 32) . This stereotypic response to diverse injuries suggests that a final common transcriptional pathway may ultimately be responsible. To date, a final common "hypertrophy gene program" has not been identified. However, alterations in many genes have been reported, including fetal cardiac isoforms, immediate-early genes, growth factors, redox genes, and members of the MAP kinase, -adrenergic, and Ca
2+
-signaling pathways among others (17, 26, 27, 30, 32) . Activation of some of these pathways (particularly fetal isoforms such as ormyosin heavy, -skeletal actin and brain natriuretic peptide) is now so widely accepted that it is often included as part of the definition of cardiac hypertrophy.
We and others have demonstrated that physiologic cardiac nitric oxide (NO) signaling opposes LVH (3, 5, 35) . In mice, deletion of nitric oxide synthases (NOS) leads to ageassociated LVH as manifested by an increase in both ventricular wall thickness and mass.
Notably, deletion of NOS3 (endothelial NOS) causes hypertrophy associated with systemic hypertension, whereas deletion of NOS1 (neuronal NOS) causes LVH with normal systemic blood pressure (3, 11) . These findings suggest that NOS1 deficiency induces LVH via loadindependent signals and, therefore, may activate a distinct transcriptional pathway. hypertrophy transcriptional programs. Because a large number of genes have been implicated in LVH pathogenesis, we employed a genomic approach using microarrays and quantitative polymerase chain reaction to analyze multiple genes simultaneously. We tested our hypothesis using three approaches: 1) exploratory analysis of differentially expressed genes in NOS -/-mice,
2) candidate-gene analysis using sets of genes implicated in LVH pathogenesis, and 3) cluster analysis comparing global patterns of gene expression. Our findings demonstrate that hypertrophied NOS3 -/-and NOS1 -/-hearts have distinct molecular phenotypes, suggesting unique roles of NOS isoforms in the pathogenesis of LVH.
Methods:
Animals: We studied transgenic mice with homozygous deletions of NOS3 or NOS1, and C57Bl/6 wild-type (WT) controls (Jackson Laboratories, Bar Harbor, ME, USA). NOS3 -/-and NOS1 -/-mice initially had a mixed background of C57Bl/6 and Sv129 and were then backcrossed at least 10 generations onto C57Bl/6 (11, 12). All experimental protocols were approved by the Animal Care and Use Committee of the Johns Hopkins University.
Microarray hybridization: Myocardial RNA was isolated from individual NOS3
and WT mice (n=3 in each group; age 20 3 months) using the Trizol reagent and Qiagen
RNeasy columns. Seven of the mice were male, and two were female (one NOS3 -/-and one
NOS1 -/-
). Individual cDNAs were prepared from each RNA isolate using reverse transcriptase (Gibco BRL SuperScript). Each cDNA was subsequently used as a template to make biotinlabeled cRNA using an in vitro transcription reaction (Enzo), resulting in a single cRNA for each heart. Each cRNA was hybridized with an individual Affymetrix MGU74A oligonucleotide array, which was subsequently processed and scanned according to the manufacturer's instructions. All arrays were hybridized in the same batch to avoid variability in hybridization conditions. Each array quantifies the expression of 12,422 transcripts (including full-length mRNA sequences and expressed sequence tag clusters) derived from build 74 of the UniGene database (www.affymetrix.com). Data were saved as raw image-files and converted into probeset data (.cel files) using Microarray Suite (MAS 5.0). All data are available for download at www.hopkins-genomics.org.
Analysis of microarray data: We used robust multi-array average (RMA) to analyze
Affymetrix probe-set data (13) . Software for RMA is available for download (www.bioconductor.org) for use in the R-package for statistical computing (www.r-project.org).
There are four stages to RMA. First, probe-set data (*.cel files) from all arrays are simultaneously normalized using quantile normalization, which eliminates systematic differences between chips, without significantly altering the relative intensity of probes within a chip. Second, mean optical background level for each array is estimated, and the intensity for each probe is adjusted to remove this. Third, the normalized, background-corrected data is transformed to the log 2 scale. Finally, a median-polish procedure is used to combine multiple probes into a single measure of expression for each gene on each array. Three types of analysis were subsequently performed on this normalized expression data as described below. -/-(6.4±0.9 mg/g) and NOS1 -/-(6.2±0.8 mg/g) mice exhibited similar increases in cardiac mass at age 20 months (28% and 25%, respectively).
Differentially expressed genes in NOS
Differentially expressed genes in NOS -/-hearts. Of the 12,422 genes and expressed sequence tags present on the microarrays, 6,409 were detected at levels higher than background in at least one of the strains (NOS3 -/-, NOS1 -/-or WT). As shown in Figure 1 , 47 genes were differentially expressed in NOS3 -/-hearts and 65 were differentially expressed in NOS1 -/-hearts compared to WT controls. A complete annotated list of these genes is available in the data supplement. We categorized each of the differentially expressed genes by known or proposed gene function (Table 1) . These genes participate in cellular responses that are universally important for cell proliferation (growth and differentiation, transcription, protein turnover, apoptosis), as well as pathways that may be related specifically to cardiac hypertrophy (structure, metabolism, stress response, redox control). A number of genes related to immunoglobulin synthesis were also differentially expressed, perhaps reflecting different degrees of immune activation in NOS3 -/-and NOS1 -/-mice compared to WT. Alternatively, they could result from different antigenic exposures in the three mouse strains. Remarkably, the direction of change in expression (increase or decrease) was similar for only 16 genes (Table 2) .
Candidate-gene analysis. Many genes previously implicated in cardiac hypertrophy were not differentially expressed in our exploratory analyses. Therefore, we performed a focused analysis using a candidate-gene approach to determine the changes in known hypertrophy genes, which may have been masked by large changes in other, perhaps less relevant, genes.
We performed a literature search to identify candidate hypertrophy genes, 71 of which were present on the MGU74a microarray. A complete list of candidates is available in the data supplement. Of these candidates, 32 (52%) were changed in at least one of the experimental strains compared to WT. These results are displayed in Figure 2 . Unlike classical models of load induced hypertrophy (24), NOS -/-hearts did not show an isoform switch from -tomyosin heavy chain or upregulation of -skeletal actin. (These genes did not meet criteria for differential expression and are not displayed in Figure 2 ). Likewise, there was no upregulation of natriuretic peptides in NOS -/-hearts. In fact, -skeletal actin and BNP were paradoxically under-expressed in the NOS1 -/-strain despite the presence of substantial LVH. We also found a potent down-regulation of myocyte-enriched calcineurin interacting protein (MCIP-1), an inhibitor of calcineurin-mediated hypertrophy (25), in the NOS1 -/-strain.
Cluster Analysis. Our results to this point suggested distinct transcriptional profiles in NOS3
-/-and NOS1 -/-hearts. To test this formally, we used hierarchical clustering. This computational method groups experimental samples into clusters according to similarity in patterns of gene expression across a large number of genes. The results are displayed in a dendrogram with short branches indicating a high degree of similarity, providing an objective way to compare relationships among samples (13) . Of the 12,422 genes and expressed sequence tags present on the microarrays, 253 were detected at levels higher than background and had a Max/Min expression ratio greater than 1.8, and were included in the clustering algorithm. Using three different similarity functions, the NOS1 -/-hearts clustered as a distinct group. In contrast, the expression profiles among NOS3 -/-and WT mice showed a higher degree of similarity, providing further evidence that the transcriptional responses to NOS3 and NOS1 deletion in the heart are distinct.
Quantitative PCR. We selected seven genes of biologic interest in LVH and validated the microarray findings in NOS3
, and WT hearts using qPCR ( Table 3) . As shown in . Neither qPCR nor microarray detected significant changes in -or -MHC in either strain. In two cases ( -skeletal actin and MCIP-1), the microarrays failed to detect changes that were detected by the more sensitive qPCR technique in the NOS3 -/-hearts. There were no disagreements among microarray and qPCR findings in the direction of change in expression compared to control.
Discussion
The principal finding of this investigation is that cardiac hypertrophy in NOS3 -/-and NOS1 -/-mice is associated with distinct transcriptional changes despite similar cardiac phenotypes. We demonstrated this using three analytic approaches: exploratory analysis of a large number of genes, candidate-gene analysis of relevant hypertrophy genes, and hierarchical clustering based on global patterns of gene expression. In addition, we validated selected microarray results using quantitative PCR as an independent methodology. Our findings support the notion that the transcriptional basis of cardiac hypertrophy can vary, with specific changes dependent upon the inciting biochemical stimulus.
Some of our findings are counterintuitive, such as the absence of changes in myosin isoforms and paradoxical decreases in BNP and -skeletal actin. However, they add to a growing literature revealing the diversity of transcriptional changes associated with hypertrophy.
Aronow et al compared expression profiles from mice with hypertrophy induced by four distinct transgenic alterations and found that no single hypertrophy program was responsible (2) . A number of functional and transgenic studies suggest that calcium/calcineurin signaling pathways play a central role in mediating hypertrophy (9, 19). However, pharmacologic inhibition of calcineurin as a strategy for preventing LVH has had mixed results (31, 36) , indicating that calcineurin signaling may not mediate all forms of hypertrophy. Studies in humans indicate that increased fetal isoform expression, which is regarded as a defining characteristic of hypertrophy in animal models, may not always accompany human heart failure. Rather, fetal isoform expression may remain unchanged, while adult isoform expression decreases (23) .
The divergent transcriptional responses in NOS3 -/-and NOS1 -/-reflect the functional specificity of NOS isoforms in the cardiovascular system (3). NOS1 is localized to the sarcoplasmic reticulum (SR) and modulates the function of the SR calcium release channel (ryanodine receptor). We have shown that deletion of NOS1 impairs basal SR calcium cycling (3). Long-term dysregulation of calcium cycling has been shown to alter cardiac gene transcription and stimulate hypertrophy (9). In contrast, NOS3, which is localized to the sarcolemma, has no effect on basal calcium cycling in the heart, but is a potent cause of systemic hypertension due to effects on the peripheral vasculature (12). These different functional Although we have emphasized the divergent transcriptional changes in NOS -/-mice, some genes showed similar changes in expression in both strains (Table 2) . Most notably, a number of heat-shock proteins are markedly reduced in both NOS -/-strains. In particular, HSP 70 is down-regulated, both on microarray and on qPCR (Fig 4a) . HSP 70 protects against adverse ventricular remodeling and prevents myocardial infarction in the setting of ischemia/reperfusion injury (4, 20) . HSP downregulation in NOS -/-hearts is consistent with previous findings that NO induces HSP70 expression via activation of the transcription factor HSF1 (34) . Impaired HSP function in NOS deficiency may contribute to worsening hypertrophy and cardiac dysfunction. Another noteworthy finding is that Bag3, an inhibitor of apoptosis, is under-expressed in both NOS -/-strains (Table 2) , consistent with the well-established role of apoptosis in cardiac hypertrophy and remodeling (6) .
Among the transgenic causes of hypertrophy explored in model systems, hypertrophy caused by NOS deletion may be especially relevant to human congestive heart failure. Heart failure is characterized by an imbalance between the formation and degradation of reactive oxygen species within the myocardium (14, 18) , and the resultant oxidative stress is sufficient to stimulate cardiac hypertrophy (21, 28) . Inactivation of NO signaling by reactive oxygen species may be one of the major mechanisms whereby oxidative stress promotes hypertrophy (10).
Moreover, treatments that have been shown to attenuate cardiac hypertrophy in heart failure (angiotensin converting enzyme inhibitors, beta-blockers, and hydralazine/nitrates), increase NO bioavailability and promote NO signaling (1, 33). Our findings identify specific transcriptional targets of NO signaling in cardiac hypertrophy, some of which may be targets for pharmacologic intervention.
Expression profiling is a powerful technique that offers tremendous promise, but it creates substantial analytic challenges resulting from the analysis of many genes in a small number of samples (22) . We addressed these at multiple levels. Of the methods to convert Affymetrix probe-set data into measures of gene expression, which include software supplied by the manufacturer, model-based methods (16) , and robust multi-array average (RMA), we chose RMA based on its superiority in the analysis of small data sets (13) . For the exploratory analyses, we used strict selection criteria to define differential gene expression in order to select biologically significant genes and to minimize spurious findings that result from multiple comparisons. Furthermore, we independently validated findings of interest using qPCR. We also used a candidate-gene approach to detect changes in highly relevant genes that could be overlooked in exploratory analyses.
Several limitations warrant mention. Microarray technologies only assess the abundance of transcripts, which may not correlate with the abundance, localization, or function of corresponding proteins. However, many genes (e.g., heat shock proteins) are principally regulated at the level of transcription, and therefore may be accurately characterized by microarrays. We chose to use the entire heart to limit the impact of tissue heterogeneity on quantification of transcript abundance; however, this prevented us from discerning chamberspecific alterations in gene transcription. This may be important in light of the tendency of NOS3 -/-mice to develop pulmonary hypertension and right ventricular hypertrophy when they are subjected to chronic hypoxemia (29 N3  N2  N1  E3  E1  WT1  E2  WT3  WT2  N3  N2  N1  E2  E3  E1  WT3  WT2  WT1  N2  N1  N3  E2  E3  E1  WT3  WT2  WT1 A. B. C. 
